|
Post by mnkdfann on Jan 18, 2019 10:37:28 GMT -5
They previously had a $500M offer on the table for 51% and refused. When / with whom was that? Is this the guy who stood up at the annual meeting and made some offer to invest bigly on behalf of some fund or something? (Seriously, IIRC there was such an incident.)
|
|
|
Post by bigchungus91354 on Jan 18, 2019 10:43:44 GMT -5
They previously had a $500M offer on the table for 51% and refused. I bet they would jump for that chance right now. Double their current MC and keep 50%
|
|
|
Post by mnkdfann on Jan 18, 2019 10:48:14 GMT -5
They previously had a $500M offer on the table for 51% and refused. I bet they would jump for that chance right now. Double their current MC and keep 50% Silly wabbit.
|
|
|
Post by mannmade on Jan 18, 2019 10:50:37 GMT -5
Imho for $500m they are not going to give up control of the company.
|
|
|
Post by compound26 on Jan 18, 2019 11:11:27 GMT -5
Imho for $500m they are not going to give up control of the company. Agree.
|
|
|
Post by mango on Jan 18, 2019 11:29:07 GMT -5
Thing is..Mannkind..doesn't need to be acquired..has fianance and outlicense deals..rolling in..7 pipe items..this Oscar can grow..already has the most awesomest drug...whats big pharma without the most awesomest drug?..overpriced slow in and out..and pretty much irrelevant...flatlined..sitting on their lorals..over billing to make up for their lazyness..just sayn...cars..beat buggies..planes beet walking..and driving..and big pharma can lie to themselves..the future is coming..they can't stop it.. At this point the worst is over. MNKD now has control over their future. Scripts will continue to grow although slowly until further SOC changes happen. The UT deals provide a bigger market cap than is currently reflected in the pps. However, MNKD provides a huge risk to BP. Up until recently the general feeling was afrezza did not really work too good based on the studies. Now, when some one says this you give them the Libre and a "small" (4u) and you have them give it a try and prove what they are saying. They can't.
The bottom line is with CGMs, afrezza and the Libre numbers do not lie. There is no longer any hiding. At the same time, Mike has some breathing room and is sitting on the biggest drug in pharma history. MannKind is without a doubt the biggest threat to BP. We have technology no one else does. We have some of the most brilliant minds working with us. Al Mann is legend. Anyone that claims MannKind's technology does not perform the way we all know it does is either a Shill or a damn fool. This company's potential isn't limited by boundaries, it's limited by capital, capital, capital. MannKind + capital is the Shorts & BP crooks worse nightmare.
|
|
|
Post by lennymnkd on Jan 18, 2019 12:04:41 GMT -5
The CGM IS THE TRIAL OF ALL TRIALS !
|
|
|
Post by longliner on Jan 18, 2019 16:03:44 GMT -5
And the share price trajectory that began on 12/27/18 continues.
|
|
|
Post by mango on Jan 18, 2019 16:18:54 GMT -5
You have to keep in mind that the purchase price has to look reasonable to the shareholders of the acquiring company or else the management of that company will not be long for this world. Most deals still get done at a 20-35% premium over a recent market price, and a handful get done at a 50% premium, but very few get done at higher prices. Today MNKD has a market cap of $258 so 150% of market is roughly $380 million. The purchaser also gets to pay off all the debt and other liabilities which adds another $250 million to the price tag. In order to get more than that, MNKD has to show much stronger fundamentals that will move the market price north of where it is. Buyers will fork out a modest premium to get an asset that fits with their portfolio, but they want to see more than hopes and dreams. Also keep in mind that with TS all the key patents are expired at this point so if that ever does become the next big thing in drug delivery there will be generic imitators emerging rapidly. That puts something of a ceiling on the value of that part of the portfolio.Will you please provide us with some examples of these key Technosphere patents that are expired? matt Still waiting... "Not to mention the entire portfolio of any Technosphere related compounds we make are protected by almost 800 patents around the world. And so it’s one of the things this IP has stated held the test time between Sanofi after all that people doing due diligence on the company overtime and now United Therapeutics. So we feel very good about our IP position." MannKind CEO Mike Castagna, Cantor Fitzgerald Global Healthcare Conference Call October 2, 2018
|
|
|
Post by mannmade on Jan 18, 2019 17:00:34 GMT -5
Not only all of the above, but for the sake of arguement let’s say all the patents have expired, TS is so complex and expensive to duplicate that Al was not concerned with generics as I recall. So logically it would be much easier for a company like Uthr, novo etc to license TS for low double digit royalties rather then take the years and expense it would need to develop their own ability.
|
|
|
Post by babaoriley on Jan 18, 2019 17:10:58 GMT -5
Imho for $500m they are not going to give up control of the company. Not with those salaries!!
|
|
|
Post by stockwhisperer on Jan 19, 2019 9:36:49 GMT -5
Rumors, Murmurs & Buzz said, yesterday, that Johnson & Johnson (JNJ) are in advanced merger discussions w/MNKD CEO & wrapping up bid. Seems, RM&B might just be a rag that hits tickers w/a dart and arbitrary puts interchangeable post it notes on them for entertainment. Just a day it two before their last two tweets, they said, MNKD CEO, to detail significant partnership agreement w/leading U.S. big pharma. Maybe there is more to RM&B - have no idea what their accuracy rate is, if they even have one. In any case, without a lot of detail, just in simple terms, what are realistic opinions of - dollar amount per share, MNKD would receive if they really did sell or merge - based on where they are trading at today ($1.40 range). Thanks.
|
|
|
Post by sportsrancho on Jan 19, 2019 9:49:38 GMT -5
I’m going with Nate’s 1-3b right now. As far as valuation. If there was ever a true leak, then the stock will run up. And then there would be a 35% premium on top of that, that’s just my speculation. And maybe a bidding war, I’ve been in stocks that’s happened to. I’ve been in stocks that have doubled on a buyout. After a big run up. The run-up most likely caused by the shorts getting out.
|
|
|
Post by sellhighdrinklow on Jan 19, 2019 9:54:31 GMT -5
Rumors, Murmurs & Buzz said, yesterday, that Johnson & Johnson (JNJ) are in advanced merger discussions w/MNKD CEO & wrapping up bid. Seems, RM&B might just be a rag that hits tickers w/a dart and arbitrary puts interchangeable post it notes on them for entertainment. Just a day it two before their last two tweets, they said, MNKD CEO, to detail significant partnership agreement w/leading U.S. big pharma. Maybe there is more to RM&B - have no idea what their accuracy rate is, if they even have one. In any case, without a lot of detail, just in simple terms, what are realistic opinions of - dollar amount per share, MNKD would receive if they really did sell or merge - based on where they are trading at today ($1.40 range). Thanks. I'd be curious if their thrown darts have ever hit a bullseye. Any knowledge of a bullseye?
|
|
|
Post by sportsrancho on Jan 19, 2019 9:59:05 GMT -5
Bristol-Myers Buys Amylin for $5.3B, Getting Diabetes Drugs
Luke Timmerman 6/29/12
[Updated: 9:40 pm] Bristol-Myers Squibb (NYSE: BMY) has pulled the trigger on a $5.3 billion acquisition of San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN).
The deal, announced late Friday, calls for New York-based Bristol to pay $31 a share for Amylin, or about 10 percent more than its closing price today. By taking on some of Amylin’s debt and a contractual obligation it has to Eli Lilly, the total value of the deal is actually about $7 billion, Bristol said in a statement. In an unusual twist, the deal also includes AstraZeneca, in which Astra is paying $3.4 billion to Bristol to get an equal split of the profit and loss from the Amylin subsidiary of Bristol.
Amylin, which has never been consistently profitable in its 25 year history and has run up a $2.7 billion cumulative deficit, found itself the object of a Big Pharma bidding war the past few months. The company recently extricated itself from a longtime partnership with Lilly, meaning it was in position to collect the bulk of revenue from its twice-daily injectable exenatide (Byetta) and the more commercially attractive new version of exenatide, which comes in a once-weekly form (Bydureon). Bloomberg News reported in March that Amylin rejected an earlier bid from Bristol-Myers, and then the news service followed that with reports that everyone from Merck, Pfizer, Sanofi, and AstraZeneca had shown interest in obtaining Amylin for its diabetes franchise.
Amylin suffered through two years of regulatory delays in its bid to win FDA approval for Bydureon, until it finally broke through and got clearance to sell the drug in the U.S. in January. The delays created an opening for a competing drug, liraglutide (Victoza) from Novo Nordisk to gain market share. Still, Amylin could get as much as $1.5 billion in annual sales from its diabetes treatments, according to a Cowen & Co. analyst cited by Bloomberg. About 25 million people in the U.S. have diabetes, and some estimate the prevalence of diabetes could double over the next 25 years as the nation’s obesity rate continues to surge.
“Amylin’s innovative diabetes portfolio, talented people and state-of-the art manufacturing facility complement our long-standing leadership in metabolics,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb, in a statement.
Amylin and Bristol didn’t say in today’s statement what will happen to Amylin’s employees or its headquarters in San Diego and manufacturing plant in Ohio. The company said it had 1,300 employees heading into this year, according to its most recent annual report. Bristol-Myers said the deal will be a drag on its profits in 2013, but that it should start to boost profits in 2014.
This is the stock I was in, that I bought it $15 on rumors of a buyout:-) And nobody tells you ahead of time guys, you don’t get to vote on, it you don’t get to hear who made other bids, all you know is the stock is going up and you can’t figure out why.
|
|